title: Long-term suppressive effect of octreotide on progression of metastatic gastrinoma with multiple endocrine neoplasia type 1: seven-year follow up.
abstract: A 30-year-old woman had a history of prolactinoma and primary hyperparathyroidism. She was diagnosed as having multiple endocrine neoplasia type 1 with gastrinoma and liver metastases. Octreotide therapy was started and the serum gastrin level decreased immediately. Octreotide continued to suppress gastrin secretion over the next 7 years. The Ki67/MIB1 proliferation index of this tumor was only 0.5 % and somatostatin receptor (SSTR) 2 expression was very strong in both 2002 and 2009. This case suggests the importance of investigating the Ki67/MIB1 index and SSTR expression in patients with metastatic gastrinoma.
authors.affiliation: Department of Endocrinology and Metabolism, Sumitomo Hospital, Osaka. megmegoo_y@yahoo.co.jp
authors.forename: Megu
authors.initials: M
authors.lastname: Yamaguchi
authors.forename: Yuya
authors.initials: Y
authors.lastname: Yamada
authors.forename: Yoshiya
authors.initials: Y
authors.lastname: Hosokawa
authors.forename: Ryuya
authors.initials: R
authors.lastname: Iwamoto
authors.forename: Sachiko
authors.initials: S
authors.lastname: Tamba
authors.forename: Arisa
authors.initials: A
authors.lastname: Ihara
authors.forename: Koji
authors.initials: K
authors.lastname: Yamamoto
authors.forename: Yoshihiko
authors.initials: Y
authors.lastname: Hoshida
authors.forename: Yuji
authors.initials: Y
authors.lastname: Matsuzawa
mesh_terms: D000328:Adult; D018450:Disease Progression; D005260:Female; D005500:Follow-Up Studies; D015408:Gastrinoma / Q000175:diagnosis / Q000188:drug therapy*; D006801:Humans; D018761:Multiple Endocrine Neoplasia Type 1 / Q000175:diagnosis / Q000188:drug therapy*; D015282:Octreotide / Q000008:administration & dosage*; D010190:Pancreatic Neoplasms / Q000175:diagnosis / Q000188:drug therapy*; D013997:Time Factors
chemical_list: D015282:Octreotide